Trial Profile
A Phase I/II Study of Chemo Radiation Plus the Anti-Programmed Death-1 (Anti-PD-1) Antibody, Pembrolizumab (MK-3475) for Locally Advanced Laryngeal Squamous Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Cisplatin
- Indications Laryngeal cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Mar 2021 Status changed from active, no longer recruiting to completed.
- 12 Feb 2020 Planned End Date changed from 1 Jan 2020 to 1 Jan 2021.
- 12 Feb 2020 Status changed from recruiting to active, no longer recruiting.